StockGlow

Absci Corporation (ABSI)

Designs antibody drugs to treat inflammatory bowel disease, hair loss, and cancer

$7.13-0.06%Healthcare
Compare ABSI with
StockGlow Score
75
Leaning Bullish
BearishBullish
1 year ago+145.9%

The outlook

ABSI is trading at $7.13 with strong analyst backing—nine analysts average a "Strong Buy" rating. The stock sits midway in its 52-week range with mixed momentum relative to moving averages. The average analyst price target implies roughly 93% upside from current levels.

What’s behind the score

Analyst consensusStrong Buy — 1.4 avg of 9 analysts
Price trendMixed vs its moving averages
52-week range50% of the way from its 52-week low to high
Price targetAvg target +93% vs current price

Analyst price target

~12-month · 9 analysts
$13.78average target+93.2% vs now
Now $7.13
Low $10.00High $17.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$1.21B
52-wk high
$12.06
52-wk low
$2.24
50-day avg
$7.93
200-day avg
$4.57
Trailing P/E
—

Similar stocks

RXRXRecursion Pharmaceuticals, Inc.$3.05+1.33%PRMEPrime Medicine, Inc.$3.09+2.66%ABOSAcumen Pharmaceuticals, Inc.$2.28+3.64%SANASana Biotechnology, Inc.$3.29+0.30%RLAYRelay Therapeutics, Inc.$18.29-1.88%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy